Connect with us

Health

Counterfeit/Falsified Drug Alert: Ozempic

Published

on

PRESS RELEASE

FROM THE MINISTRY OF HEALTH AND HUMAN SERVICES

 

Cockburn Town, Turks and Caicos Islands, 2nd May 2025: In response to a U.S. Food and Drug Administration (FDA) alert relating to the identification of hundreds of counterfeit/falsified Ozempic(semaglutide) 1mg injection in the U.S. drug supply chain, the Ministry of Health and Human Services (MoHHS) wishes to alert all pharmacies, other healthcare providers and consumers to be vigilant when procuring this product from online or instore vendors who source this medicine from the US supply chain.

According to the FDA alert, Novo Nordisk – the genuine manufacturer – issued the initial notification revealing that the counterfeit Ozempic was distributed outside their authorised supply chain in the U.S. Medical products are considered counterfeit/falsified when their identity, composition or source are deliberately or fraudulently misrepresented. Ozempic is used to treat hyperglycaemia (high blood sugar) in type 2 diabetes mellitus in adults, adolescents and children over 12 years of age. It is also used to treat obesity.

Importantly, Novo Nordisk revealed that the counterfeit product’s label displays the following:

  • lot number PAR0362 (which is authentic) and
  • an illegitimate serial number starting with the first eight digits 51746517.

Novo Nordisk has indicated that only when both the lot number and the first eight digits 51746517 are used together should the product be considered counterfeit.  Neither Novo Nordisk nor the FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product. Therefore, if used, these counterfeit products may result in the ineffective treatment of patients due to incorrect dosage, contamination with harmful substances, or use of unknown or substituted ingredients. This may pose serious risks – that could be life-threatening – to health because they are administered by subcutaneous injection. Notably, the FDA is aware of six adverse event reports linked with this lot, however, none of them appear to be associated with the counterfeit product.

The Minister of Health and Human Services – Hon. Kyle R. Knowles, and the MoHHS’ top priority is to ensure public health safety and so in light of this update are imploring all wholesalers, retail pharmacies and other healthcare professionals to:

  1. Examine all Ozempic products received from within the US supply chain.
  2. Administer, dispense, distributeor sell the counterfeit Ozempic labelled with lot number PAR0362 and serial number starting with the first eight digits 51746517.
  3. Quarantine all remaining stock(s) of the counterfeit pens for possible disposal by the Environmental Health Department (contact: 338-2142).
  4. Notify your overseas suppliers for any additional information.

Patients/consumers are encouraged:

  1. Not to useany counterfeit Ozempic 1mg injection labelled with lot number PAR0362 and serial number starting with the first eight digits 51746517.
  2. To contact their physicians and/or pharmacist if they have any questions or concerns before using any Ozempic 1mg injection.
  3. To purchase Ozempic 1mg injection only from authorised pharmacies and not online stores.
  4. To report any suspected side effects associated with Ozempic 1mg injection via the MoHHS Adverse Drug Reaction Form found at https://gov.tc/docs/ADR.pdf.

For further information, please contact André Morgan, National Pharmacist at: (649)338-3072 or amorgan@gov.tc.

Continue Reading

Health

Chile becomes the first country in the Americas to be verified by WHO for the elimination of leprosy  

Published

on

Santiago/Washington, D.C./Geneva, 4 March 2026 (PAHO/WHO) – The World Health Organization (WHO), together with the Pan American Health Organization (PAHO), congratulates Chile for becoming the first country in the Americas—and the second globally—to be officially verified as having eliminated leprosy disease.

Leprosy (Hansen disease) was historically recorded in Chile at the end of the 19th century on Rapa Nui (Easter Island). The disease was limited in mainland Chile, with sporadic introductions, contained through isolation and treatment measures in the Island, where the last secondary cases were managed by the late 1990s.

Since then, Chile has not reported any locally acquired case of leprosy for more than 30 years, with the last locally acquired case detected in 1993. However, the disease was never removed from the country’s public health agenda; it has remained a notifiable condition, monitored through mandatory reporting, integrated surveillance, and continuous clinical readiness across the health system.

“This landmark public health achievement is a powerful testament to what leadership, science, and solidarity can accomplish,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Chile’s elimination of leprosy sends a clear message to the world: with sustained commitment, inclusive health services, integrated public health strategies, early detection and universal access to care, we can consign ancient diseases to history.”

The verification recognizes more than three decades of sustained public health action, robust surveillance, long-term political commitment, and a health system that has remained vigilant even in the absence of local transmission.

“Chile’s achievement demonstrates that eliminating leprosy is achievable and requires building strong systems that can detect, respond to, and provide comprehensive care for people affected by the disease, including those living with chronic disabilities,” said PAHO Director Dr. Jarbas Barbosa. “Being the first country in the Americas to be confirmed as eliminating leprosy sends a powerful message to the Region—that diseases strongly linked to groups living in vulnerable conditions can be eliminated, contributing to interrupt the vicious circle between disease and poverty.”

At the request of Chile’s Ministry of Health, PAHO and WHO convened an independent expert panel in 2025 to assess whether elimination had been achieved and could be sustained over time. The panel conducted a thorough assessment, reviewing epidemiological data, surveillance mechanisms, case management protocols, and sustainability plans. Its findings confirmed the absence of local transmission and validated Chile’s capacity to detect and respond to future cases occurring among the non-autochthonous population.

“This is very good news and a source of great pride for our country. Chile has received verification of the elimination of leprosy disease, becoming the first country in the Americas and the second globally to achieve this recognition,” said Ximena Aguilera, Chile’s Minister of Health. “This milestone reflects decades of sustained public health efforts, including prevention strategies, early diagnosis, effective treatment, continuous follow-up, and the commitment of health teams across the country. It also reaffirms our responsibility to maintain active surveillance and ensure respectful, stigma-free care for all.”

Sustained training, surveillance and holistic care in a low-incidence setting

Between 2012 and 2023, Chile reported 47 cases nationwide, none of which were locally acquired.

Chile’s integrated model ensures early detection and comprehensive care: primary care centers serve as the entry point for suspected cases, with timely referrals to specialized dermatology services for diagnosis, treatment, and follow-up. Clinicians receive training aligned with WHO’s Towards zero leprosy strategy. The system prioritizes early intervention, disability prevention, and holistic care, including physiotherapy and rehabilitation services, ensuring that anyone affected by leprosy receives continuous support for both acute and long-term health needs to promote full recovery and social inclusion.

A milestone for the Region of the Americas

Chile’s accomplishment paves the way for other nations, illustrating the impact of political will, cross-sector collaboration, and adaptive planning in low-incidence settings.

Since 1995, PAHO, in coordination with WHO, has provided multidrug therapy (MDT) free of charge to countries in the Americas, including Chile. This uninterrupted access to treatment, combined with national supply systems, has been essential to curing patients, preventing disability, and interrupting transmission.

PAHO has also supported Chile in aligning surveillance with international standards, strengthening laboratory capacity, and maintaining clinical expertise in a low-incidence context, where many health professionals may never encounter a case during their careers.

Ensuring access and coverage for everyone

Chile’s elimination of leprosy has been achieved within a broader legal and social framework that protects human rights, promotes inclusion, and prevents discrimination. National legislation guarantees equal access to health care, social protection, and disability services, ensuring that people affected by leprosy receive care without stigma or exclusion.
Chile’s mixed public–private health system, with strong regulatory oversight, further strengthens equitable access, including for migrants and other vulnerable populations.

Sustaining elimination

Aligned with WHO’s Towards zero leprosy strategy and PAHO’s Disease Elimination Initiative, Chile’s experience demonstrates that elimination is not defined solely by the absence of disease, but by a sustained health system capable of detecting, responding to, and providing holistic care whenever a case appears.

Moving into the post-elimination phase, Chile is encouraged to continue reporting to WHO, maintain sensitive surveillance, and ensure that clinical expertise is retained for future sporadic cases as well as any cases acquired outside the country. The verification panel also recommended formally designating a referral centre and leveraging WHO Academy’s online training for health workers and staff, strengthening long-term capacity and preparedness.

Continue Reading

Health

TCI Hospital Celebrates Successful “Heart Strong TCI” Initiative During Heart Month

Published

on

(Providenciales – Monday, March 2, 2026) TCI Hospital proudly announces the successful achievement of its Heart Strong TCI initiative, a comprehensive Heart Month campaign focused on raising awareness and strengthening cardiovascular disease prevention efforts across the Turks and Caicos Islands.

Heart disease remains the leading cause of death in the Turks and Caicos Islands, highlighting the critical need for sustained public education, risk-factor reduction, and early intervention. The Heart Strong TCI initiative was designed to actively engage the community through education, outreach, and physical activity.

Key Activities Included:

Educational Training Sessions

Healthcare professionals conducted structured sessions addressing hypertension, diabetes, cholesterol management, nutrition, exercise, smoking cessation, and the early warning signs of heart disease.

House Call Talk Show Feature

A dedicated Heart Month episode of the hospital’s House Call program provided expert discussion on cardiovascular risk factors and prevention strategies, empowering viewers with practical, evidence-based guidance.

Red Fridays Awareness Campaign

Throughout the month, staff wore red every Friday to increase visibility around heart disease awareness and reinforce the campaign’s message within the community.

Heart Strong 5K Walk/Run

In collaboration with the Rotary Club, TCI Hospital hosted a community-wide 5K walk/run to promote physical activity as a cornerstone of heart health. The walk/run also provided an opportunity for community screening.

Digital Health Education Campaign

To expand its reach, TCI Hospital also shared ongoing heart health education tips and prevention messages across its social media platforms, including Facebook, LinkedIn, and Instagram. These posts provided actionable guidance on diet, exercise, blood pressure control, and lifestyle modification, and encouraging community members to learn CPR.

Heart Strong TCI: A Continuous Commitment

While Heart Month has officially ended, Heart Strong TCI represents an ongoing institutional commitment to cardiovascular disease prevention and awareness. TCI Hospital will continue to prioritize:

  • Community-based education initiatives
  • Preventative screening and early detection programs
  • Lifestyle and wellness promotion
  • Strategic partnerships that advance public health outcomes

“Heart Strong TCI is not limited to a single month,” CEO, Dr. Denise Braithwaite-Tennant.  “Cardiovascular disease prevention requires sustained effort. We remain committed to promoting healthy hearts across the Turks and Caicos Islands year-round.”

For more information about cardiovascular health services or upcoming screening initiatives, please contact TCI Hospital at 649-941-2800 in Providenciales, 649-941-2900 in Grand Turk or email us at info@interhealthcanada.tc

About TCI Hospital

TCI Hospital is dedicated to delivering high-quality healthcare services to the people of the Turks and Caicos Islands, with a strong emphasis on prevention, education, and community wellness.

Continue Reading

Health

What to Look for with Self-Checks at Home

Published

on

February is National Self- Check Month and family medicine physician at Cleveland Clinic, OH, John Hanicak, MD, highlights why at home self-checks are extremely important when it comes to not just early cancer detection but identifying other illnesses too and offers tips on what to look out for.

“Sometimes Ilook at them as sort of like your check engine light on the car, just like therewould be a red flashing light that tells you that there’s something wrong with acar and prompts you to bring that in and get serviced. Your body does the samething. It gives you warning signs tolook intothat symptom a little bit further,” said Hanicak.

Dr. Hanicak saidself-checks are going to be a little different for everyone. 

However, in general, he recommends looking for anything that may seem abnormal, such asunexplained weight loss,blood in your urine, bumps and bruisesthat won’t heal,and changes in bowel habits. 

For example, if you suddenly start going to the bathroom a lot more than you used to, that could bea signof something more serious. 

He also suggestsdoing regular skin checksanddocumentingany molesor spotsthat start to look different. 

“Realize that you are your own person.There’s nobody else in the world exactly like you.You’ve got your own set ofideas, your own family history and your own genetics.Know what is normal for you, and when that changes, that’s the kind of thing thatwe would be interested in talking about,” said Dr. Hanicak. 

Dr. Hanicaknotes that self-checks are not meant to replace cancer screenings, as those are just as important to keep up with. 

Press Release: Cleveland Clinic

Continue Reading

FIND US ON FACEBOOK

TRENDING